EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age

Adam S Faye iD, David T Rubin, Corey A Siegel, Millie D Long, Nabeel Khan, Silvio Danese iD, Peter M Irving, Raymond K Cross, Irina Blumenstein, Alessandro Armuzzi, Sara N Horst, Axel Dignass und 9 weitere

Inflammatory Bowel Diseases · 2026

DOI: 10.1093/ibd/izaf258 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Inflammatory Bowel Diseases, 2026. Verfasst von Adam S Faye und 20 weiteren Autor:innen. Beteiligte Einrichtung: NYU Langone Health, New York, NY, United States. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Oxadiazoles, Indans, Sphingosine 1 Phosphate Receptor Modulators. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, Bristol Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Older adults with ulcerative colitis (UC) have unique treatment challenges. Ozanimod is approved for the treatment of moderately to severely active UC in adults based on the phase 3 True North (TN) study results. Here, we analyzed the impact of patient age on ozanimod safety and efficacy in TN and during the open-label extension (OLE).

Methods

Patients were stratified by age at TN baseline: <40, 40 to 60, and >60 years (cutoff: 75 years). Safety was evaluated in all patients during TN and the OLE; efficacy was assessed at weeks 10 and 52 in TN and up to OLE week 190 in patients who entered as TN week 52 ozanimod clinical responders.

Results

Of 1012 patients analyzed, 492 were <40 years of age, 404 were 40 to 60 years of age, and 116 were >60 years of age. Infection, malignancy, cardiac events, and macular edema were low throughout TN across all ages. Exposure-adjusted incidence rates (EAIRs) of opportunistic and serious infections increased with age during the OLE. Patients ≥40 years of age had higher hypertension EAIRs than those <40 years of age, but EAIRs of other cardiovascular TEAEs were low. No cases of progressive multifocal leukoencephalopathy occurred over 242 weeks of ozanimod exposure. Efficacy rates for evaluated clinical and mucosal endpoints at weeks 10 and 52 with ozanimod were generally consistent across age groups with the overall population; similar trends were observed in the OLE.

Conclusions

Ozanimod safety was similar and efficacy was generally comparable across age groups, although statistical significance vs placebo was not achieved in patients >60 years of age.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeOxadiazolesIndansSphingosine 1 Phosphate Receptor ModulatorsHumansAdultFemaleMiddle AgedMaleAgedAge FactorsSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

inflammatory bowel diseaseulcerative colitis

Substanzen

ozanimodOxadiazolesIndansSphingosine 1 Phosphate Receptor Modulators

Autor:innen und Institutionen

  • NYU Langone Health, New York, NY, United States.
  • University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, United States.
  • Walter and Carole Young Center for Digestive Health, Dartmouth-Hitchcock Medical Center, Lebanon, NH, United States.
  • Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
  • Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, United States.
  • Department of Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy.

ORCID-Profile: Adam S Faye, Silvio Danese, Taku Kobayashi

Förderung

  • NIA NIH HHS
  • Bristol Myers Squibb

Zitieren

APA

Faye, A. S., Rubin, D. T., Siegel, C. A., Long, M. D., Khan, N., Danese, S., Irving, P. M., Cross, R. K., Blumenstein, I., Armuzzi, A., Horst, S. N., Dignass, A., Kobayashi, T., Lawlor, G., Krakovich, A., Petersen, A., Liu, Z., Wang, D., Jain, A., …, & Sabino, J. (2026). Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf258

Vancouver

Faye AS, Rubin DT, Siegel CA, Long MD, Khan N, Danese S, et al. Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izaf258

BibTeX
@article{Faye2026,
  author = {Faye, Adam S and Rubin, David T and Siegel, Corey A and Long, Millie D and Khan, Nabeel and Danese, Silvio and Irving, Peter M and Cross, Raymond K and Blumenstein, Irina and Armuzzi, Alessandro and Horst, Sara N and Dignass, Axel and Kobayashi, Taku and Lawlor, Garrett and Krakovich, Anthony and Petersen, AnnKatrin and Liu, Zhaohui and Wang, Dong and Jain, Anjali and Ananthakrishnan, Ashwin N and Sabino, João},
  title = {Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age},
  journal = {Inflammatory Bowel Diseases},
  year = {2026},
  doi = {10.1093/ibd/izaf258}
}
Kostenlos starten →